Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
William GrossmanInterim Chief Medical Officer | enGene TherapeuticsENGN | Open-market buy | 09/22 | 09/24 | 5,102 sh | $1.97 | $10,050.94 | No record |
enGene TherapeuticsENGN | Open-market buy | 24/10/30 | 24/11/01 | 561,797 sh | $8.90 | $4,999,993.3 | +22.7% | |
Forbion Growth Management B.V.10% Owner | enGene TherapeuticsENGN | Open-market buy | 24/10/30 | 24/11/01 | 561,797 sh | $8.90 | $4,999,993.3 | +22.7% |
enGene TherapeuticsENGN | Open-market buy | 23/12/27–24/10/08 | 24/10/18 | 470,633 sh13 trades | $6.40avg. | $3,013,458.33 | +23.5% | |
enGene TherapeuticsENGN | Open-market buy | 23/12/27–24/10/08 | 24/10/18 | 470,633 sh13 trades | $6.40avg. | $3,013,458.33 | +23.5% | |
enGene TherapeuticsENGN | Open-market buy | 24/09/27 | 24/10/01 | 10,000 sh | $5.70 | $57,000 | No record | |
enGene TherapeuticsENGN | Open-market sale | 24/04/18–24/04/22 | 24/04/22 | 52,529 sh3 trades | $15.00avg. | $787,980.75 | −1.7% |
